Member Info for NathanR999

An achievement that the significance of which might get lost as it doesn't come with tangible pound notes. Lab accreditation is vital and as we deal with more and more nasdaq or pe held biotechs and deepen our engagement with the large primarily us based mega pharma this certification will ensure we get a decent bite of cherry for the site services component and will improve margins. We have to have a lab in hvivo but just doing work for our challenge studies will eat into margin but maximising capacity across field study work and to act as a contract lab for early stage projects keeps everyone busy and Will ensure we sweat assets properly. Good news

That was directed at short everything by the way....

How to tell us you don't understand the company and dont own shares without telling us you don't understand the company and don't own shares. F***wit clown.

To managed expectations here re polb001 results. Unlikely to be getting anything until every last subject is dosed as it is all double blinded, meaning no one.knows who is in each study group. The unblinding will likely only take place once all biomarkers and downstream testing needed to show efficacy (or not) of polb001 is complete. Then topline results can be shared. This may take a little while depending on turnaround of dosing of patients with the LPS. and how long any lab tests take on patient samples. Some might be quick some might be much longer depends on the biomarker . I am not expecting much before November/December but happy to be surprised! The discussions for licensing may take a good number of weeks or months. However if the trials shows the asset does what it says then it's game on. That is the key pivotal gateway, poor performance or minimal effects will likely means onto the next asset and sp might not be so forgiving - pharma development is tough and very few get out of early stages. That said this asset has some real attractive use cases if it works that have, I feel, been undersold. If the LPS challenge shows polb001 inhbits overactive immune response then flu,covid (acute severe, maybe long covid) sepsis are all on table for potential investigation. To get it to final saleable approved product has a lot of larger p2/3 trials to work needing loads of funding- if we get 25-50m and downstream milestones that could be considered a result, anything over 50m and milestones and royalties etc will be truly amazing. Keep your fingers crossed peeps.

Although in coming years Poolbeg will most certainly be contracting Orph for challenge studies to prove in P1 or early P2 of drug development cycle that their Polb002 works as it says for Flu (and maybe other targets) . Other future assets thrown out by the AI analysis of the challenge study samples for Flu and RSV will likely take same route. Could be 1 or 2 studies a year from Poolbeg heading to Orphs coffers. BOTH company's offer extraordinary potential for capital gains over the next 3-5 years esp vs current depressed share price.

Cough* mobileye cough* 18p doesn't even reflect the progress made since it last it 12p. 50% market share roughly 200mil post tax profits even at a basic pe of 10 would be 2bn company more.likely pe of 20-30. I don't think a quid is fantasy I slightest.

Agree, all could be interested. Hopefully we have positive news over next 6 months, penny drops over what that means to future revenue and we end up in a bidding process as the price.marches higher to acquire. Will be severely disappointed with anything under a £1 a share. Don't get me wrong my average is 9.3p and a price in the 20s will mean a decent return and seeingmachines becomes a 1bn company at 25p ish but it would be a real damp squib vs potential here i feel. £1 and I could retire at 50 with a decent income at £3 or more a share and my family are set for life across several generations I think. Execution is playing out in front of us.. ...

My 3-5yr mcap target is 350 million or 50p a share.

Based on growth of study revs growing to c100m per year and this would be based on current flu/rsv work continuing at levels we see now with 10% annual growth. Added to this would be 1 or 2 corona studies and 1 or 2 malaria studies. I would also expect 1 or 2 novel models to be developed in this time with onward sales potential in a 5 year period I would expect at least 1 of these to be delivering revenue. Throw in core support services via Venn and hvivo labs (assumption of ISO and CAP accreditation being approved) growing at 10-15% with support as a trial site for p3 vaccine population studies to utilise the flucamp screening individuals more fully. I would expect a CRO acquisition of Orph at 50% premium and have a rough target in my mind of 75p per share based on the above coming to pass. The stranded assets are difficult to value. PREP is nominal for me - potentially less than 5mil as the CHIM data previously generated by hvivo was unconvincing for me IMHO. Imutex share is valuable but tied to conserv/ seek and not sure what games they are playing. Worth nothing until tide turns on Flu infection numbers turn to make a p3 study viable. In a perfect world this would be worth 5 to 10p a share to orph holders but not holding breath here. To further build out case to support my suggested valuation is cost and effort to build 10 or so challenge models would be more than current orph market cap, the goodwill, experience,reputation in this area and contacts in phama for infectious diseases also underpins this.

Bear case is execution risk, world turning its view due to.geopolitics away from infectious diseases. A challenger company coming in to replicate offer in a low cost market such as Eastern Europe or India. Sales cap out at a maximum of 75m a year or new assets dry up thay would haven previously needed a CHIM study and real cash generation is negligible for longer. Always a risk of a challenge going wrong and killing a patient in infectious diseases (although all clinical trials from pre p1 to p3 have inherent risk and patients die and even launched products have associated deaths - arthritis drugs being a risk historically leading to product withdrawals)

My tuppence worth and for full disclosure I hold 800k shares across my portfolios at an average of around 12p. I am confident that holding for 3 to 5 years will be wealth building for me. Those holding at prices in the High 30s and low 40s will still see an uplift and see return of capital at least although of course some opportunity costs.

I see a grossly miss priced company at the moment with unique offer which should be reflected on its valuation. Those that had the Poolbeg spin out shares will derive significant value if they hold.longer term that could be in advance of even the best bull case for orph.

Looks like according to a few ipo tracking sites that ipo maybe Monday now?? Anyone know anymore to clarify?

Green shoots of positive movement. Long way to go for me to break even across my holdings. c9.03p but it's a start! GLA!

IF all those large prints are buys then that's just over 1% of shares issued. Would be very happy to see another institutional buyer taking a position here on the open market rather than us issuing a new tranche of shares at half the price of the last large buy in. Seeing a few green shoots across a number of my portfolio shares that have had a haircut over last year so I hope they aren't pruned back as a false dawn. A few days of 5 or 6 % rise over next few weeks will be a welcome respite from the long grind down since Xmas. Good luck all.

Definitely disappointing to see share price where it is, unfortunately we have some challenging times financially for people to navigate and some will be managing their finances to cope with rising prices pretty much across the board. Some PIs may need to liquidate some positions to ensure they have enough to meet their family needs. Difficult choices need to be made and those holding here and able to hold challenged positions in their portfolio will, I have zero doubt on this, see returns more consistent with historic highs and aligned with those target sp's indicated in broker notes. If you are able to navigate these choppy waters without need to liquidate to pay bills - you should count yourself lucky and take some care to understand somw peoples motivation to sell- it may not be something they want. However , the contracts keep being signed and firming next yeats revenue too which is a great sign and hopefully of a smoothing of revenues vs lumpy years and lean years. Still hold all that I have and haven't sold anything and is my second largest overall position behind seeing machines (again a market leader in its area way below its true and future value) Again, I hold these as a long 3-7 year prospect and feel.my research backs both Orph and See for considerable upside.

Thanks for the clarification, wasn't sure if the model they mentioned was maybe still on old idrive version not the new version 8 which is believed to be SEE in the tech. Did think the i4 with SEE was from 2023 at some point but hadn't realised law governing speed - learnt something today many thanks ?? N

The 40mph thing is that more likely smarteye? Didn't they have that limitation? I thought ewe functioned across a much higher range of speeds.?

Torque monitoring or haptic sensing of steering wheel I think will be phased out and won't score much and maybe even zero in ncap scores. Camera will be natural solution once eu and us rules kick in as they will be able to see that eyes are on road, touch onnsteering wheel or torque can be cheated and doesn't mean attention. I thinknonce manufacturer has a camera in board (ideally in the mirror;-) ) it will want to offer OMS and leverage the profitability as camera cost is already sunk in DMS. I think it will be camera based dms in all vehicles and OMS in range toppers at first then filtering down ranges as uptake surges and r&d/initial manufacturer cost are recouped. Just.my humble opinion. I think guardian being already ready for fleet might be the route for oem trucks as many will be fitted out for larger fleet customers with monitoring/telematics solutions already. A build in dash no doubt will come and once on oem does it others will follow. The price sucks currently but even with new hires I cant see cash being burnt that rapidly that needs a cash call this year - maybe one of them larger holders are rebalanced risk in portfolios - difficult market so someone maybe managing capital exposure based on strict internal rules and we are collateral damage. The story has for at least the last two years been about late 2024 or 2025.onwards for volume, the rns we have seen over last 6 months have been great and deals can slip in time for all sorts of reasons outside of seeingmachines control. They will happen, the visibility of these no doubt will arrive soon enough - trying to be zen in this. Is technology mandated - yes. Do we have a good solution - yes, are we announcing new business wins - yes are we seeing value of competitors wins above our own - no. Do we have clear technical advantage and some novel IP/know how in key camera optimal positioning such as a mirror -yes. Will other companies win some business - yes , certainly as car industry likes not to have eggs in one basket. Do we have other strong opportunities and relationships in areas outside of auto - yes Do we see revenue growing q on q moving forward- yes Will each quarter of growth and cash inflow reduce risk or overall capital raise should one be required - yes. This is a business close to a hockey stick of income increase with read across to other businesses like mobileye that went on to have general roll out of their tech area in high volume auto that are or have been valued many many times above SEE currently. I am definitely in this for the ride, if the story significantly changes through contract loss, other players entering with better products etc then I will reassess. Smarteye, Cipia and others will also likely need to raise money too and they.may need it sooner so may find conditions more choppy. Still incredibly confident that may investment here although underwater by quite a bit will deliver me gains that will be wealth changing.

Not sure mobileye actually have a dms solution themselves unless I haven't read the article correctly- it suggests the eyeQ chip could run it and might be an option for us or smarteye. Would they buy smarteye as hardware agnostic as a quick solution but then risk being locked out by backing wrong horse. No doubt its all very secret on the rfq win side for everyone not just see. I have my fingers crossed that the assumed wins for us is conservative Nd out share of market across all options goes over 50%

Not sure mobileye actually have a dms solution themselves unless I haven't read the article correctly- it suggests the eyeQ chip could run it and might be an option for us or smarteye. Would they buy smarteye as hardware agnostic as a quick solution but then risk being locked out by backing wrong horse. No doubt its all very secret on the rfq win side foe everyone.

I had forgotten how high institution holding was, I had just looked at SEE IR page with disclosed holdings of top 10 holdings but 70% is even better with less free float. End game for me is still 18 months away and from a personal point I would like the price under 12p for another couple of months to add more if I get some other investments trending up to recycle into SEE. If any bids for see come in early so be it, just hope it piques interest from more than just Magna and QC. Would be nice for Intel, nvidia, tesla to chip in too. Exciting stuff but patience of a zen Buddhist needed on the waiting front!!!

Reiterates 20p but further suggestive of increased market share and further upside as discount reduces as wins and revenue become clearer.

Nearly 200% upside from.where we are now. GLA

We must be getting close to the point that those shares in private investors shares will be sought-after by institutional buyers. Rough estimate of 50% of shares with large institutional or technology partners ie.magna. So if a smart institution wanted to take 2 to 5% stakes that will likely tighten the pool trading daily and force price higher. Let's say 10 smaller tech or growth type funds chase 25% of see then surely that will really put a jet engine under the SP. If I was a fund manager in this space I would be seriously considering take a stake of some significance and price today would be amazing for that fund. Only.small concern is that our current cash gets us to likely profitablity but an opportunity to.license or acquire accretive technology that needs funding. This might be used as a way to get another institution in a t a lower price. End result is obviously earning enhancing for SEE but I wouldn't be keen for more share issues at this price. But we are in an absolute monster of share I feel and fore personally holding 2mill shares across isa and sipp it could transform several generations of my family in the future and open opportunity for them that I never had growing up should a bidding war for see arise and drive share north of £1. I wait with bated breath!!!!